**Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016**

Description: Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016

**Summary**

‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Diffuse Large B-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

**Scope**
- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undiscovered stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diffuse Large B-Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Diffuse Large B-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma

**Reasons to buy**
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction
Diffuse Large B-Cell Lymphoma Overview
Therapeutics Development
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance
Diffuse Large B-Cell Lymphoma - Products under Development by Companies
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment
Drug Profiles
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates
Diffuse Large B-Cell Lymphoma - Dormant Projects
Diffuse Large B-Cell Lymphoma - Dormant Projects
Diffuse Large B-Cell Lymphoma - Discontinued Products
Diffuse Large B-Cell Lymphoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2016
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H1 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H1 2016
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2016
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H1 2016

List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2016

Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753844/
Office Code: SCPLJFCO

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>□</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>□</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>□</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [ ] [Mrs] [ ] [Dr] [ ] [Miss] [ ] [Ms] [ ] [Prof] [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World